Back to top
more

Orthofix Medical (OFIX)

(Delayed Data from NSDQ)

$12.54 USD

12.54
539,742

+0.23 (1.87%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $12.53 -0.01 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Genomic Health's Cost Pressure Mounts, Cancer Tests Strong

by Zacks Equity Research

Concerns related to Genomic Health's (GHDX) strong dependence on breast cancer tests still linger. Also, higher production cost and expenses continue to weigh heavily on the company's margins.

    Zacks Equity Research

    Integra Rides High on Product Launches, Competition Rife

    by Zacks Equity Research

    Integra LifeSciences' (IART) latest launch of new sizes of SurgiMend and PriMatrix and Omnigraft as well as continued growth in private label products is encouraging.

      Zacks Equity Research

      Henry Schein to Offer CAS' Fully-Automated Cognivue Device

      by Zacks Equity Research

      Henry Schein (HSIC) is consistently working toward boosting its Medical segment.

        Zacks Equity Research

        Hill-Rom (HRC) Rides on Product Launches, Competition Rife

        by Zacks Equity Research

        Hill-Rom (HRC) focuses on product innovation through research and development. Its product launches slated for the fourth quarter are boosting investors' confidence.

          Zacks Equity Research

          Integra LifeSciences' SurgiMend PRS Meshed Boosts ADM Line

          by Zacks Equity Research

          Advancing its portfolio of acellular dermal tissue matrix for plastic and reconstructive surgery, including breast reconstruction, Integra LifeSciences (IART) launched SurgiMend PRS Meshed in Europe.

            Zacks Equity Research

            Boston Scientific's Apama Deal to Boost Electrophysiology Arm

            by Zacks Equity Research

            Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.

              Zacks Equity Research

              Capricor Therapeutics (CAPR) Looks Good: Stock Adds 13.9% in Session

              by Zacks Equity Research

              Capricor Therapeutics (CAPR) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.

                Zacks Equity Research

                Quest Diagnostics Buys 2 Outreach Labs, Widens Customer Base

                by Zacks Equity Research

                Quest Diagnostics (DGX) completes acquisition of outreach laboratory services of two Hartford HealthCare hospitals. The deal is expected to widen the network of the company.

                  Zacks Equity Research

                  Abbott Gets FDA Nod for FreeStyle Libre, Boosts Diabetes Arm

                  by Zacks Equity Research

                  Abbott's (ABT) diabetes care segment to strengthen with the FDA approval for FreeStyle Libre Flash glucose monitoring system.

                    Zacks Equity Research

                    Edwards Lifesciences Pipeline Impressive, Currency Woes Stay

                    by Zacks Equity Research

                    Edwards Lifesciences (EW) rides high on product launches as well as strength in the global Transcatheter Aortic Valve Replacement market.

                      Zacks Equity Research

                      Quest Diagnostics to Buy Shiel to Widen Footprint in NY-NJ

                      by Zacks Equity Research

                      After the completion of Shiel's acquisition, the medical lab is expected to expand Quest Diagnostics' (DGX) physician and patient service centers network in the New York-New Jersey area.

                        Zacks Equity Research

                        Stryker (SYK) to Gain From Solid Portfolio and Acquisitions

                        by Zacks Equity Research

                        Stryker Corporation (SYK) has successfully expanded its product portfolio over time, which aids the company to cater to evolving demands of customers.

                          Zacks Equity Research

                          Here's Why You Should Invest in Orthofix International Now

                          by Zacks Equity Research

                          Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation.

                            Tirthankar Chakraborty headshot

                            New Strong Buy Stocks for September 22nd

                            by Tirthankar Chakraborty

                            Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

                              Zacks Equity Research

                              Quidel Corporation (QDEL) Jumps: Stock Rises 6.5%

                              by Zacks Equity Research

                              Quidel Corporation (QDEL) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.

                                Zacks Equity Research

                                Orthofix (OFIX) is a Great Momentum Pick for You: Here's Why

                                by Zacks Equity Research

                                Banking on a number of favorable metrics, Orthofix (OFIX) stands out as one of the most suitable momentum stock.

                                  Zacks Equity Research

                                  Anika (ANIK) Grows in Orthopedic Medicines on Positive Data

                                  by Zacks Equity Research

                                  Anika Therapeutics' (ANIK) data shows HYALOFAST as an effective treatment option for cartilage lesions, suitable to all age groups.

                                    Zacks Equity Research

                                    Orthofix (OFIX) Earnings Meet, Sales Beat Estimates in Q2

                                    by Zacks Equity Research

                                    Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation businesses. Moreover, raised full-year 2017 guidance buoys optimism.

                                      Zacks Equity Research

                                      Zacks Industry Outlook Highlights: Varian Medical Systems, Inogen, Edwards Lifesciences, Orthofix International and INSYS Therapeutics

                                      by Zacks Equity Research

                                      Zacks Industry Outlook Highlights: Varian Medical Systems, Inogen, Edwards Lifesciences, Orthofix International and INSYS Therapeutics

                                        Zacks Equity Research

                                        MedTech Industry Outlook - July 2017

                                        by Zacks Equity Research

                                        The overall expectation is that President Trump's legislative change for MedTech will result in lower taxes and regulation for the industry as a whole.

                                          Zacks Equity Research

                                          MedTech Industry Outlook - March 2017

                                          by Zacks Equity Research

                                          A shrinking customer base indicates an impending slash in the demand for expensive medical procedures and devices.

                                            Zacks Equity Research

                                            Orthofix International (OFIX) Looks Good: Stock Jumps 9.9%

                                            by Zacks Equity Research

                                            Orthofix International N.V. (OFIX) moved big last session, as its shares jumped almost 10% on the day.